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We have previously reported the establishment of a Staphylococcus aureus laboratory strain, 10*3d1, having
reduced susceptibility to daptomycin and heterogeneous vancomycin-intermediate S. aureus (VISA) phenotype.
The strain was generated in vitro by serial daptomycin selection (Camargo, I. L., H. M. Neoh, L. Cui, and K.
Hiramatsu, Antimicrob. Agents Chemother. 52:4289–4299, 2008). Here we explored the genetic mechanism of
resistance in the strain by whole-genome sequencing and by producing gene-replaced strains. By genome
comparison between 10*3d1 and its parent methicillin-resistant Staphylococcus aureus (MRSA) strain
N315IP, we identified five nonsynonymous single nucleotide polymorphisms (SNPs). One of the five muta-
tions was found in the rpoB gene encoding the RNA polymerase  subunit. The mutation at nucleotide position
1862 substituted the 621st alanine by glutamic acid. The replacement of the intact rpoB with the mutated rpoB,
designated rpoB(A621E), conferred N315IP with the phenotypes of reduced susceptibility to daptomycin and
hetero-VISA. The rpoB(A621E)-mediated resistance conversion was accompanied by a thickened cell wall and
reduction of the cell surface negative charge. Being consistent with these phenotypic changes, microarray data
showed that the expression of the dlt operon, which increases the cell surface positive charge, was enhanced in
the rpoB(A621E) mutant. Other remarkable findings of microarray analysis of the rpoB(A621E) mutant
included repression of metabolic pathways of purine, pyrimidine, arginine, the urea cycle, and the lac operon,
enhancement of the biosynthetic pathway of vitamin B2, K1, and K2, and cell wall metabolism. Finally,
mutations identified in rplV and rplC, encoding 50S ribosomal proteins L22 and L3, respectively, were found
to be associated with the slow growth, but not with the phenotype of decreased susceptibility to vancomycin and
daptomycin, of 10*3d1.
Daptomycin, a semisynthetic chemical derived from Strepto-
myces roseosporus, is a cyclic lipopeptide antibiotic having bac-
tericidal activity against a broad range of aerobic and anaerobic
Gram-positive bacteria (1, 27, 29, 48). The exact mechanism of
action for daptomycin has not been fully elucidated yet. How-
ever, it is generally accepted that daptomycin binds to the
cytoplasmic membrane of Gram-positive bacteria via calcium-
dependent binding (27). Once bound, the lipopeptide tail of
the molecule is inserted into the bacterial cell membrane. This
tail serves as an ion channel through which an efflux of potas-
sium, and potentially other ions, can pass through, thereby
causing the bacterial cell to rapidly depolarize. Depolarization
results in multiple failures in the DNA, RNA, and protein
synthesis of the bacteria, ultimately resulting in a rapid bacte-
rial cell death (27, 47). As daptomycin has a rapid bactericidal
activity, it is approved in the United States and the European
Union as an alternative option for the treatment of infections
caused by S. aureus (44, 49).
Although daptomycin has a potent bactericidal activity
against methicillin-resistant S. aureus (MRSA), it tends to have
less antimicrobial activity against vancomycin-intermediate S.
aureus (VISA) clinical strains (17, 43). Various groups re-
ported that MRSA with reduced susceptibility to vancomycin
and/or daptomycin were generated during the treatment with
either vancomycin or daptomycin (21, 26, 32, 42). Recently, we
reported the establishment of a laboratory MRSA strain
10*3d1 having dual heteroresistance to daptomycin and
vancomycin by serial daptomycin selection (6). Despite its se-
lection by daptomycin alone, this strain expressed raised resis-
tance to both daptomycin and vancomycin, a thickened cell-
wall, and a partially overlapped transcription profile with that
of hetero-VISA (6). Here we explored the genetic mechanism
for the dual heteroresistance of the strain 10*3d1. Using
whole-genome sequencing and gene replacement experiments,
we proved that a nonsynonymous mutation in rpoB, the gene
that codes for the ß subunit of the bacterial DNA-dependent
RNA polymerase, was responsible for the phenotypic conver-
sion.
MATERIALS AND METHODS
Bacterial strains and growth conditions. Staphylococcus aureus strain
N315IP is a derivative of strain N315, in which the repressor mecI was inacti-
vated and the beta-lactamase plasmid was cured (31). The genotype of inacti-
vated mecI and absence of the beta-lactamase plasmid is characteristic of recent
Japanese methicillin-resistant S. aureus (MRSA) (23). 10*3d1 is an N315IP
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derivative with a daptomycin-nonsusceptible and vancomycin-heteroresistant
phenotype, obtained by gradual daptomycin exposure as described previously
(6). Clinical VISA isolates Mu50 and MI, their vancomycin-susceptible in vitro
derivatives Mu50-P35 and MI-P84, and respective VISA revertants Mu50-PR
and MI-PR described elsewhere previously (13, 14) were used as control strains
in some experiments. Among these two isogenic triple sets of VISA phenotype-
associated S. aureus strains, all VISA strains are daptomycin nonsusceptible (17).
All the strains were grown in brain heart infusion (BHI) broth (Difco, Detroit,
MI) at 37°C with aeration if not otherwise indicated. For each experiment, an
overnight culture was diluted 100-fold in prewarmed fresh BHI broth and further
incubated with aeration to ensure exponential growth condition before sampling.
The cell growth was monitored by measuring the optical density of the culture at
578 nm (OD578) with a spectrophotometer (Phamacia LKB Biotechnology, Inc.,
Uppsala, Sweden).
Genome sequencing and SNP detection of daptomycin-nonsusceptible S. au-
reus strain 10*3d1 with short reads. 10*3d1 genome sequencing was performed
using the Solexa/Illumina genome analyzer (Illumina, Inc., San Diego, CA), a
recently introduced highly parallel genome sequencer. The chromosomal ge-
nome sequence of N315 (accession number BA000018) was used as a scaffold to
assemble and orient the reads. In a duplicated run of this instrument, a total of
5,833,472 36-bp-long reads were collected, giving a total coverage of an about
74.5 genome equivalent. Short reads were then aligned to the N315 genome
using a short-read mapping program of MetaGenomeGambler PRO (MGG),
version 2.1.2 (In Silico Biology, Inc., Yokohama, Japan) with parameters of a
seed size of 12 bp and a maximum gap size allowed on a read of 3 bp to generate
primary single nucleotide polymorphism (SNP) calls. Only uniquely mapped
reads were retained by setting values of 1 for cost to both open and extend a
gap and of 15 for cutoff overlap length. We filtered SNP calls and combined them
into a single list using the Assemble program of MGG, and the resulting SNPs
were verified by manually inspecting multiple alignments of all short reads
mapping to each SNP locus. The identified SNPs were then verified by rese-
quencing of the corresponding loci of N315 and 10*3d1 genomic DNAs, together
with resequencing the corresponding loci of N315IP (its whole-genome se-
quence was determined recently [28]), a parent strain of 10*3d1. The resequenc-
ing was performed using an Applied Biosystems 3730 capillary sequencer (Ap-
plied Biosystems Japan Ltd.) with forward and reverse primers for each locus.
Complete-genome comparisons of N315IP and 10*3d1 using NimbleGen
microarray. Complete genome comparison of 10*3d1 and its parent strain
N315IP was performed using an array-based service (CGS) provided by Roche
NimbleGen, Inc. (Madison, WI). Briefly, the test (10*3d1) and reference
(N315IP) genome DNA samples were separately cleaved to pools of low-
molecular-weight fragments and labeled with fluorescent dyes, Cy3 and Cy5,
respectively. The labeled samples were then competitively hybridized to a
NimbleGen CGS whole-genome tiling array, which was generated with the S.
aureus N315 genome sequence as a reference. Resulting hybridization signals
were analyzed using NimbleScan, version 2.5, software, and the signal ratio of the
number of reference samples to the number of test samples for all probes were
plotted versus N315 genomic position. The locations of probes along the ge-
nome, which have a significant ratio shift between reference and test probes for
both strands, represent the possible sequence differences, including SNPs, dele-
tions, sites of insertion, endpoints of inversions, or translocations. Those loca-
tions indicated were checked by PCR and resequencing of both test and refer-
ence genomic DNA.
Electron microscopic evaluation of cell wall thickness. Preparation and exam-
ination of S. aureus cells by transmission electron microscopy were performed as
described previously (15). Morphometric evaluation of cell wall thickness was
performed using photographic images at a 30,000 final magnification. Thirty
cells of each strain with nearly equatorial cut surfaces were measured for the
evaluation of cell wall thickness, and results were expressed as mean value 
standard deviation (SD).
Antimicrobial susceptibility testing. The MICs of several antimicrobials were
measured for the constructed mutants and parent strains using Etest strips (AB
Biodisk, Sweden). For the daptomycin MIC, the medium was supplemented with
50 mg/liter Ca2 calcium according to Clinical and Laboratory Standards Insti-
tute (CLSI) criteria (7). A sterile cotton swab was immersed in a 0.5 McFarland
standard of tested bacterial culture before streaking on sterile Mueller-Hinton
(MH) agar plates. The antimicrobial strips were applied after 10 min. Plates were
then incubated at 37°C and read after 24 h.
Analysis of daptomycin- and vancomycin-resistant subpopulations (popula-
tion analysis). The population analysis shows how many cells in a fixed number
of cells (usually about 107 CFU) of each strain are resistant to various concen-
trations of antibiotics. Overnight cultures of tested strains in BHI broth were
adjusted to an OD578 of 0.3. Tenfold dilutions of these cell suspensions were then
prepared, and 0.1 ml of each suspension was spread on BHI agar plates con-
taining various concentrations of daptomycin or vancomycin. Plates were incu-
bated for 48 h at 37°C, and the log number of CFU was plotted against dapto-
mycin or vancomycin concentration.
Growth curve and doubling time. A portion of fresh bacterial culture was
diluted to about 1  105 CFU/ml bacterium cells in 10 ml fresh BHI broth and
grown at 37°C with 25-rpm shaking in a photo-recording incubator (TN-2612;
Advantec, Tokyo, Japan). The OD was monitored automatically every 2 min, and
cells were grown to an OD600 of 1.0. For growth curve and doubling time
determination, OD versus time in the exponential growth phase of each strain
was plotted. Doubling times were then calculated as follows: doubling time 
[(t2  t1)  log 2]/[log OD600 at t2  log OD600 at t1].
Time-kill assay. Time-kill methodology was used to test the strain’s suscepti-
bility to daptomycin. A final inoculum of about 1  106 CFU/ml bacterium cells
was used. Prior to inoculation, each tube of fresh cation-adjusted Mueller-
Hinton broth with 50 g/ml CaCl2 was supplemented with daptomycin at con-
centrations of 0.5, 1, 2, 4, and 8 g/ml. A tube without antibiotic was used as a
growth control. The culture tubes were incubated in the TN-2612 incubator at
37°C for growth curve recording. Viability counts were performed at 0, 2, 4, 8,
and 24 h by plating serially diluted cultures on MH agar plate. The growth
inhibition effect of daptomycin was also evaluated by plotting the bacterial
growth curve.
Introduction of chromosomal point mutations by a targeted sequence substi-
tution method. Plasmid pKOR1 constructed by Bae and Schneewind is an Esch-
erichia coli/S. aureus shuttle vector which has been described as facilitating allelic
replacement in S. aureus without the use of antibiotic markers (3). It permits
rapid cloning via lambda recombination and ccdB selection in E. coli, while
selection of knockout clones without plasmids in S. aureus is accomplished by
anhydrotetracycline-mediated induction of pKOR1-encoded secY antisense tran-
scripts, as secY is essential for S. aureus growth (3). To introduce the chromo-
somal point mutations identified in the drug-resistant mutant into its drug-sensitive
parent strain, this method was utilized with some innovation as described previously
(16, 38). Briefly, instead of cloning the up- and downstream fragments of a target
gene into pKOR1 (as done in knockout experiments [3]), the gene in-frame
containing the intended nucleotide sequence was amplified from sequence-donor
strain 10*3d1 using primers that contain attB1 (5-GGGGACAAGTTTGTACAA
AAAAGCAGGCT-) and attB2 (5-GGGGACCACTTTGTACAAGAAAGCTG
GG-) sites on the respective up- and downstream sequences. This fragment was then
cloned into pKOR1. Following cloning and ccdB selection in E. coli, the constructed
plasmid was then introduced into strain N315IP by electroporation using Bio-Rad
GenePulser Xcell (Bio-Rad Laboratories, Inc., Hercules, CA) with the setting pa-
rameters described previously (31). Overnight culture of plasmid-carrying clones at
43°C selects for single crossover mutants that carry both mutated and corrected
nucleotides. Single crossover mutants were then cultured in drug-free broth to
facilitate plasmid excision and subjected to anhydotetracycline induction, whereby
only nonplasmids carrying mutants could survive. To check for successful intro-
duction of the mutations, resulting mutants were checked for the target se-
quences via sequencing the corresponding region with forward and reverse prim-
ers which were located 50 to 100 bp beyond the primers used in cloning. By using
this strategy, the chromosomal point mutations identified in drug-resistant strain
10*3d1 were introduced into drug-sensitive parent strain N315IP.
Determination of whole-cell zeta potential. Zeta potential is a useful indicator
of electronic charge of colloidal suspensions or emulsions (5, 51). The zeta
potential was determined using zeta potential analyzer DelsaNano HC (Beck-
man Coulter, Inc., CA). Suspensions of 105 cells/ml in 10 mM phosphate-buff-
ered saline (PBS), pH 7.4, were applied for triplicate analysis in each experiment.
Briefly, the microelectrophoresis chamber was filled with a bacterial suspension,
and a voltage difference of 100 V was applied over the chamber. Data represent
the means and standard deviations from three independent experiments and are
presented by the ratio of change in the zeta potential of resistant strain versus
control strain. The zeta potential change ratio (percentage) was calculated as
follows: {1  [(Zt  Zc)/Zc]}  100, where Zt and Zc represent zeta potential
of test and control, respectively.
RNA preparation and microarray analysis. Bacteria to be tested were grown
in 10 ml BHI broth to exponential phase (OD600  0.6) before harvest. Pellets
were then suspended with precooled T10E10 buffer (10 mM Tris-HCl [pH 8.0]),
and lysostaphin solution (WAKO, Japan) at 3.0 g/ml final concentration was
added. The suspensions were then incubated at 37°C for 3 min until complete cell
lysis occurred. Immediately, 7 ml of acidic phenol (pH 5.2, equilibrated with 20
mM sodium acetate) was added, and 600 l 3 M sodium acetate was added. The
samples were then frozen and thawed 3 times at 80°C and 65°C, respectively.
Phenol-chloroform extraction and ethanol precipitation were then carried out.
After that, the resulting RNA pellet was subjected to digestion with RNase-free
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DNase I (Roche, Mannheim, Germany) at 37°C for 30 min. The RNA samples
were then purified again with phenol-chloroform extraction and ethanol precip-
itation. Pellets were then resuspended in 25 l diethyl pyrocarbonate (DEPC)-
treated water. The construction and analysis of the DNA microarray have been
described previously (13).
Statistical analysis of data. The statistical significance of the data was evalu-
ated with Student’s t test.
Microarray data accession number. Transcriptional profiles of RpoB621E mu-
tation-related strains may be found under CIBEX accession no. CBX135.
RESULTS AND DISCUSSION
Comparison of the chromosomes of 10*3d1 and N315IP.
To study the mechanism of daptomycin resistance in S. aureus,
we have established MRSA strain 10*3d1 with reduced sus-
ceptibility to daptomycin (6). The strain was derived from
N315IP, a daptomycin- and vancomycin-susceptible labora-
tory MRSA strain (6, 28, 31) by serial daptomycin selection.
The strain unexpectedly showed decreased susceptibility to
both daptomycin and vancomycin and expressed some of the
VISA characteristics of thickened cell wall and decreased
growth rate, as well as the transcription profile partially over-
lapping that of hetero-VISA (6). Since we noticed cross-resis-
tance of VISA clinical strains to vancomycin and daptomycin
in early 2006 (17), the unexpected acquisition of the dual
resistance by 10*3d1 prompted us to carry out a whole-genome
comparison of 10*3d1 and N315IP and a gene replacement
experiment to clarify the genetic basis for the phenomenon.
Our strategy was (i) whole-genome sequencing of the 10*3d1
chromosome and identifying SNPs in comparison with its iso-
genic parent strain N315IP and (ii) introduction of the SNPs
into the N315IP chromosome by single-gene replacement to
test the effect of the mutations on vancomycin and daptomycin
susceptibilities.
We employed two methods for SNP detection: whole-ge-
nome sequencing by using a Solexa/Illumina genome analyzer
and competitive DNA hybridization using the NimbleGen mi-
croarray provided by Roche NimbleGen, Inc. These two meth-
ods were complementary to each other in terms of the SNP
detection sensitivity and accuracy and genome scale coverage.
Table 1 lists the SNPs detected by the above two methods and
confirmed by manual validation resequencing. A total of 5
SNPs located in 4 distinct genes were identified, all of which
caused amino acid substitution.
Exploring the effect of SNPs of 10*3d1. To test which SNP is
responsible for the raised vancomycin and daptomycin resis-
tance, we introduced the SNPs one by one into the N315IP
chromosome. We used a targeted sequence substitution
method for the SNP introduction (16, 38), whereby the SNPs
were introduced directly on the chromosome without insertion
or deletion of any additional sequence or antibiotic selection
markers.
(i) The effect of the SA1826 mutation. Open reading frame
(ORF) SA1826 encodes a conserved hypothetical protein with
TABLE 2. SNP type, antibiotic susceptibility profile, and doubling time of S. aureus strains used in this study
Strain
Sequence typea MIC (mg/liter) by Etestb Doubling
time
(min)
Reference
for strainsRpoB621 SA182614 rplV1	3 RplC120 RplC135 Daptomycin Vancomycin Oxacillin Rifampin
N315IP A A ATG G G 0.38 0.5 48 (256)c 0.006 35.73 6
10*3d1 E E ATA D A 2 3 
256 0.006 61.17 6
N315IP-rpoB621A A A ATG G G 0.25 0.25 
256 0.006 38.22 This study
N315IP-rpoB621E E A ATG G G 1.5 3 
256 0.006 39.31 This study
N315IP-SA182614A A A ATG G G 0.25 0.5 
256 0.006 36.75 This study
N315IP-SA182614E A E ATG G G 0.25 0.5 
256 0.006 36.83 This study
10*3d1-SA182614A E A ATA D A 1.5 3 
256 0.006 66.46 This study
10*3d1-SA182614E E E ATA D A 1.5 3 
256 0.006 70.54 This study
10*3d1-SA182614A-
rpoB621A
A A ATA D A 0.25 0.75 
256 0.006 59.61 This study
10*3d1-SA182614A-
rpoB621E
E A ATA D A 1.5 3 
256 0.006 72.12 This study
a Substituted amino acids are given, except for rplV, for which the mutated initiation codon (first three nucleotides) is given. A, alanine; E, glutamic acid; G, glycine;
D, aspartate.
b Etest was performed with Mueller-Hinton agar, and the results were read after 24 h of incubation at 37°C.
c MIC for the minority subpopulations is given in parentheses.
TABLE 1. List of nucleotide differences between N315IP and 10*3d1 chromosomes
SNP no.a
Position on
N315
genome
Nucleotide N315 genome information Amino acid
change
(N315310*3d1)bN315 N315IP 10*3d1 ID Gene Product
S-1 581481 C C A SA0500 rpoB RNA polymerase beta chain A621E
S-2 2065641 G G T SA1826 Hypothetical protein A14E
S-3 2305476 C C T SA2042 rplV 50S ribosomal protein L22 c
S-4 2307902 C C G SA2047 rplC 50S ribosomal protein L3 (BL3) G120D
S-5 2307947 C C T SA2047 rplC 50S ribosomal protein L3 (BL3) G135A
a “S” stands for single nucleotide polymorphism (SNP).
b The number denotes the position of amino acid substitution. The left amino acid is that of N315, and the right that of 10*3d1. A, alanine; E, glutamic acid; G,
glycine; D, aspartate.
c The initiation codon is changed from ATG to ATA.
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its two domains similar to penicillinase repressor and type III
secretion needle MxiH. We first introduced the SA1826 mu-
tation into N315IP, constructing N315IP-SA182614E and
N315IP-SA182614A (Table 2). The latter was a revertant
from the recombination intermediate strain regaining the orig-
inal intact SA1826 gene. Such revertants were obtained in
every allelic replacement procedure and used as isogenic con-
trol strains throughout this study (Table 2). The constructed
mutant strains were then determined for their susceptibilities
to daptomycin and vancomycin. Etest determinations found no
difference of daptomycin and vancomycin susceptibilities be-
tween N315IP-SA182614E and N315IP-SA182614A (Table
2), indicating that the SA1826 mutation was not responsible for
the altered drug resistance phenotype in 10*3d1.
(ii) The effect of the rpoB mutation. Next, we introduced the
mutated rpoB into N315IP, obtaining strains N315IP-
rpoB621E and N315IP-rpoB621A (Table 2). To validate if the
rpoB(A621E) mutation is a unique genetic alteration during
the N315IP-rpoB621E construction, we performed the whole-
genome sequence comparison between N315IP-rpoB621E
and N315IP using the NimbleGen microarray. We found no
detectable mutation except for rpoB(A621E) in the N315IP-
rpoB621E in comparison to N315IP (data not shown), sup-
porting the hypothesis that phenotype changes of N315IP-
rpoB621E were caused by the rpoB(A621E) mutation. rpoB
encodes the  subunit of the bacterial RNA polymerase. RpoB
is a well-known target of action of rifampin, and its mutation is
frequently associated with resistance to rifampin. The position
of the mutation in 10*3d1, however, was found outside the
previously identified rifampin resistance regions of RpoB
known to confer rifampin resistance (2, 36). In fact, the muta-
tion was not accompanied by rifampin resistance in either
10*3d1 or N315IP-rpoB621E (Table 2). However, susceptibil-
ity tests showed that the rpoB(A621E) mutation caused a si-
multaneous increase of daptomycin and vancomycin MICs; the
increment of daptomycin MIC was from 0.25 mg/liter to 1.5
mg/liter, and that of the vancomycin MIC was from 0.25 mg/
liter to 3.0 mg/liter (Table 2). The extent of MIC changes were
comparable to that between N315IP and 10*3d1; N315IP
had a daptomycin MIC of 0.38 mg/liter and a vancomycin MIC
of 0.5 mg/liter, whereas it was 2.0 mg/liter and 3.0 mg/liter,
respectively, for 10*3d1 (Table 2 and Fig. 1).
(iii) The effect of rplV and rplC mutations. All our trials
failed to introduce the mutations identified in rplV and rplC of
10*3d1 into N315IP with unknown reason. To evaluate the
effect of the two mutations in the ribosomal protein genes
collectively, we changed the strategy of experiments. Instead of
introducing mutations into N315IP, we sequentially cured the
SA1826 and rpoB mutations of 10*3d1, obtaining the strain
10*3d1-SA186214A-rpoB621A which harbors mutations only in
the two rpl genes compared to N315IP. The obtained mutant
strain retained the slow growth phenotype of 10*3d1. Thus, it
appears that the rplV and rplC mutations were the cause for the
FIG. 2. Growth curve characteristics of strains exhibiting two
groups of different growth rates. Note that strains having rplC and rplV
mutations (see Table 2) showed significantly slower growth than those
without rplC and rplV mutations.
FIG. 1. Daptomycin (A) and vancomycin (B) MICs were determined by Etest for N315IP-rpoB621E and its relevant strains. Note that
N315IP-rpoB621E has reduced daptomycin and vancomycin susceptibilities similar to those of 10*3d1.
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slow growth of 10*3d1. As shown in Table 2, restoration of the
rpoB mutation but not the SA1862 mutation of 10*3d1 led to
a significant decrease of both daptomycin and vancomycin
resistance to the susceptible levels of N315IP, while there
was no susceptibility change in the control strain 10*3d1-
SA186214A-rpoB621E. This clearly indicated that the mutations
of rplV and rplC alone had no significant effect on vancomycin
and daptomycin resistance. This experiment also confirmed
that the rpoB(A621E) mutation alone is responsible for the
dual heteroresistance to vancomycin and daptomycin.
Slow growth has been repeatedly reported for VISA strains
and is considered one of the factors associated with VISA
phenotype expression in S. aureus (10, 14, 19, 46). In our
previous study, 10*3d1 showed a significantly decreased
growth rate compared to its daptomycin- and vancomycin-
susceptible parent strain N315IP (6). We considered that the
slow growth was associated with the expression of the resis-
tance phenotype (6). However, as shown in Table 2 and Fig. 2,
the rpoB-restored strain 10*3d1-SA186214A-rpoB621A retained
the slow growth phenotype of 10*3d1 after having lost the
vancomycin and daptomycin dual resistance. Thus, the slow
growth rate itself did not influence the MIC values in any
significant way.
Although the slow growth phenotype did not raise MIC
values, it may affect the bactericidal activities of daptomycin
and vancomycin. To test this possibility, we evaluated the
growth inhibition and time-kill effect of daptomycin against
N315IP and 10*3d1-SA186214A-rpoB621A. The two strains
had the same susceptibility to bactericidal effects of daptomy-
cin irrespective of the difference in the growth rates (Fig. 2 and
Fig. 3). Thus, the slow growth rate was not a major contributor
in the reduced susceptibility to daptomycin and vancomycin of
10*3d1.
The rpoB(A621E) mutation confers daptomycin and vanco-
mycin heteroresistance to N315IP. The introduction of the
rpoB(A621E) mutation in N315IP raised MICs for daptomy-
cin and vancomycin as shown in Table 2. We previously showed
that the types of daptomycin and vancomycin resistance ex-
pressed by strain 10*3d1 were heterogenous (6). In order
to determine if the resistance pattern conferred by the
FIG. 3. Growth inhibition (A) and time-killing effect (B) of daptomycin against strains N315IP and 10*3d1-SA182614A-rpoB621A. Killing
activity is presented as log10 CFU/ml.
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rpoB(A621E) mutation was heterogeneous or not, we analyzed
the resistant subpopulation profile of the rpoB(A621E)-carry-
ing strain against vancomycin and daptomycin. Figure 4 shows
the results. Population analysis showed that N315IP-
rpoB621E, compared to N315IP-rpoB621A and parent strain
N315IP, had a significant increase in resistant subpopulations
for both daptomycin and vancomycin, and the pattern of the
population curves were similar to that of 10*3d1. Therefore, the
rpoB(A621E) mutation alone could cause the heterogenous resis-
tance phenotype of 10*3d1 against daptomycin and vancomycin.
Friedman et al. (18) recently reported a finding of two strains with
RpoB mutations, Ile9533Ser953 and Ala10863Val1086, in a series of
FIG. 5. Transmission electron microscopic observation of N315IP-rpoB621E and its isogenic strains. Transmission electron microscopy was
carried out on N315IP-rpoB621E (D), which was generated from N315IP (A) by substitution of its rpoB gene with that of 10*3d1 (B), and
experimental control strain N315IP-rpoB621A (C), which retained the intact rpoB gene. Magnification is 30,000. The values given under each
picture are the means and standard deviations of each strain’s cell wall thickness in nanometers. Note that the cell walls of N315IP-rpoB621E and
10*3d1 were much thicker than those of the control and parent strains.
FIG. 4. Analysis of daptomycin- and vancomycin-resistant subpopulations of N315IP-rpoB621E and its isogenic strains. The number of colonies
on plates containing various concentrations of daptomycin (A) and vancomycin (B) was counted after 48 h of incubation at 37°C.
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laboratory-derived S. aureus strains with decreased susceptibil-
ity to daptomycin. However, the two strains with the rpoB
mutation also carried additional mutations in mprF and yycG.
Furthermore, since they did not find the rpoB mutations in a
collection of clinical isolates with decreased susceptibility to
daptomycin, the role of the rpoB mutation was not explored
any further. In this study, by using a gene replacement method,
we unequivocally proved that an rpoB mutation can be a cause
of dual heteroresistance to vancomycin and daptomycin.
rpoB(A621E) mutation causes thickening of the cell wall.
How does the rpoB mutation cause reduced susceptibility to
daptomycin and vancomycin? The most significant feature of
the VISA phenotype is cell wall thickness (11, 14, 22). The
feature is directly associated with the “peptidoglycan-clogging
mechanism” that prevents the passage of vancomycin across
the thickened peptidoglycan layers (12). Unlike vancomycin,
daptomycin does not have binding sites in the peptidoglycan,
so the clogging effect may not apply to daptomycin resistance.
However, daptomycin has a relatively bigger molecular size
than vancomycin (molecular weight, 1,620.67 versus 1,485.7).
Moreover, daptomycin forms oligomers with calcium ions,
which dissociates only when the oligomers come close to the
bacterial membrane (45). Therefore, the thickened peptidogly-
can layer may serve as an obstacle for the access of daptomycin
to the cell membrane. In agreement with our hypothesis (17),
10*3d1 showed a significantly thickened cell wall compared to
that of its drug-susceptible parent strain N315IP (6). Figure 5
shows the electronmicrograph showing that the strain
N315IP-rpoB621E harboring the rpoB(A621E) mutation had a
much more thickened cell wall than that of the control strain
N315IP-rpoB621A. The extent of the cell wall thickening was
1.60 times, which was comparable to the case of 10*3d1 (whose
cell wall was thicker by 63% than that of its parent strain
N315IP) (Fig. 5). Therefore, the rpoB mutation is considered
to contribute to the heteroresistance to vancomycin and dap-
tomycin by thickening the cell wall.
Decreased negative cell surface charge associated with the
rpoB mutation. Decreased negative cell surface charge has
been reported as one of the contributing factors for the in-
creased daptomycin and vancomycin resistance in S. aureus
(25, 33, 52), based on the charge repulsion mechanism assump-
tion. Daptomycin and vancomycin are relatively positively
charged at a neutral pH (4, 8, 20, 24). Therefore, if a bacterial
cell generates a less negative cell surface, it would reduce the
binding of vancomycin and daptomycin molecules to the cell
(25, 33). In the case of daptomycin, however, there has been a
discrepant observation that the increased negative cell surface
charge is observed in in vitro-selected daptomycin-nonsuscep-
tible mutants (34). Therefore, the charge repulsion mechanism
might not be generally applicable or not in its simplest form. In
any case, to test the contribution of the cell surface charge in
our in vitro-selected strains, we determined the whole-cell sur-
face charge of the constructed mutants with some control
strains. The cell surface charge was measured by determining
the bacterial zeta potential, which is an indicator of the elec-
tronic charge of colloidal suspensions (5, 51). A total of
two groups of strains were used for the zeta potential deter-
mination. The first group consisted of N315IP-rpoB621E,
N315IP-rpoB621A, 10*3d1, and N315IP. The second group
consisted of clinical VISA strains Mu50 and MI and their
derivative substrains, passage-derived vancomycin-susceptible
strains Mu50-P35 and MI-P84, and Mu50-PR and MI-PR,
which were derived from the vancomycin-susceptible deriva-
tive strains by selection with 4 mg/liter of vancomycin (14).
Their vancomycin and daptomycin MICs were as follows: the
vancomycin MICs for Mu50, Mu50-P35, and Mu50-PR were 6,
2, and 6 mg/liter, respectively, and those for MI, MI-P84, and
MI-PR were 7, 1, and 6 mg/liter, respectively. The daptomycin
FIG. 6. Decrease of whole-cell negative charge in daptomycin- and vancomycin-resistant strains. Whole-cell zeta potential, an indicator of the
cell electronic charge, was determined at pH 7.4, and the zeta potential change ratio (percentage) (box bar) of the test strain (filled box) to its
respective control (open box) was calculated as follows: {1  [(Zt  Zc)/Zc]  100}, where Zt and Zc represent the Zeta potential of tthe est and
control, respectively. Values are means  standard deviations.
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TABLE 3. Transcriptional profiles of RpoBA621E mutation-related strains
ORF ID Gene Products
Ratio of signal intensitya
N315IP-
rpoB621E/
N315IP
10*3d1-SA182614A-
rpoB621E/10*3d1-
SA182614A-rpoB621A
10*3d1/
N315IP
Purine metabolism
SA0016 purA Adenylosuccinate synthase 0.36 0.64 0.76
SA0373 xprT Xanthine phosphoribosyltransferase 0.64 0.40 0.12
SA0374 pbuX Xanthine permease 0.55 0.42 0.10
SA0375 guaB Inositol-monophosphate dehydrogenase 0.90 0.50 0.18
SA0376 guaA GMP synthase (glutamine hydrolyzing) 0.88 0.65 0.23
SA0468 Hypoxanthine-guanine phosphoribosyltransferase homologue 1.51 1.18 1.53
SA0916 Similar to phosphoribosylaminoimidazole carboxylase PurE 0.84 0.80 0.72
SA0917 purK Phosphoribosylaminoimidazole carboxylase carbon dioxide-
fixation chain PurK homolog
0.93 0.54 0.43
SA0918 purC Phosphoribosylaminoimidazolesuccinocarboxamide synthetase
homolog
1.00 0.57 0.43
SA0919 Conserved hypothetical protein 0.96 0.69 0.45
SA0920 purQ Phosphoribosylformylglycinamidine synthase I PurQ 1.10 0.52 0.32
SA0922 purF Phosphoribosylpyrophosphate amidotransferase PurF 0.81 0.52 0.26
SA0923 purM Phosphoribosylformylglycinamidine cyclo-ligase PurM 0.77 0.54 0.29
SA0924 purN Phosphoribosylglycinamide formyltransferase 0.79 0.56 0.30
SA0925 purH Bifunctional purine biosynthesis protein PurH 0.75 0.59 0.33
SA0926 purD Phosphoribosylamine-glycine ligase PurD 0.61 0.55 0.36
SA1052 gmk Guanylate kinase homolog 0.81 0.91 0.81
SA1172 Similar to GMP reductase 0.34 0.37 0.57
SA1173 Conserved hypothetical protein 0.28 0.33 0.58
SA1461 apt Adenine phosphoribosyl transferase 0.94 1.30 1.41
Pyrimidine metabolism
SA0440 tmk Thymidylate kinase homolog 0.64 0.60 0.74
SA0719 trxB Thioredoxine reductase 0.45 0.46 0.68
SA1041 pyrR Pyrimidine operon repressor chain A 0.17 0.35 0.82
SA1042 pyrP Uracil permease 0.14 0.21 0.41
SA1043 pyrB Aspartate transcarbamoylase chain A 0.13 0.22 0.41
SA1044 pyrC Dihydroorotase 0.15 0.25 0.39
SA1045 pyrAA Carbamoyl-phosphate synthase small chain 0.18 0.28 0.40
SA1046 pyrAB Carbamoyl-phosphate synthase large chain 0.18 0.32 0.38
SA1047 pyrF Orotidine-5-phosphate decarboxylase 0.22 0.40 0.40
SA1048 pyrE Orotate phosphoribosyltransferase 0.20 0.43 0.41
SA1049 Hypothetical protein 0.22 0.42 0.47
SA1439 udk Uridine kinase 0.68 0.74 1.32
SA2375 Similar to dihydroorotate dehydrogenase 0.62 0.75 0.56
Arginine metabolism and
urea cycle
SA0175 Conserved hypothetical protein 0.34 0.42 0.24
SA0176 Similar to N-acetylglutamate 5-phosphotransferase 0.63 0.76 0.64
SA0177 argJ Arginine biosynthesis bifunctional protein homolog 0.61 0.76 0.64
SA0178 argC N-acetylglutamate gamma-semialdehyde dehydrogenase 0.59 0.73 0.65
SA0179 Ornithine aminotransferase 0.64 0.80 0.82
SA0821 argH Argininosuccinate lyase 0.44 0.54 0.27
SA0822 argG Argininosuccinate synthase 0.48 0.59 0.29
SA2082 ureA Urease gamma subunit 0.37 0.26 0.28
SA2083 ureB Urease beta subunit 0.23 0.19 0.24
SA2084 ureC Urease alpha subunit 0.30 0.21 0.24
SA2085 ureE Urease accessory protein UreE 0.26 0.19 0.24
SA2086 ureF Urease accessory protein UreF 0.30 0.27 0.29
SA2087 ureG Urease accessory protein UreG 0.44 0.33 0.32
SA2088 ureD Urease accessory protein UreD 0.39 0.30 0.32
SA2428 arcA Arginine deiminase 2.82 2.75 1.45
SA2429 Similar to arginine repressor 3.62 6.20 2.27
Galactose metabolism
SA0123 Similar to UDP-glucose 4-epimerase (gale-1) 0.34 0.45 0.41
SA0236 Similar to PTS fructose-specific enzyme IIBC component 0.68 0.83 0.82
SA0237 Similar to PTS, galactitol-specific IIB component 0.65 0.71 0.93
SA0238 gatC Probable PTS galactitol-specific enzyme IIC component 0.64 0.81 1.28
SA1521 pfk 6-Phosphofructokinase 0.77 0.60 0.53
SA1991 lacG 6-Phospho-beta-galactosidase 0.33 0.73 1.75
SA1992 lacE PTS system, lactose-specific IIBC component 0.35 0.63 1.40
SA1993 lacF PTS system, lactose-specific IIA component 0.32 0.62 1.38
SA1994 lacD Tagatose 1,6-diphosphate aldolase 0.39 0.59 1.25
SA1995 lacC Tagatose-6-phosphate kinase 0.38 0.56 1.22
SA1996 lacB Galactose-6-phosphate isomerase LacB subunit 0.42 0.53 1.17
SA1997 lacA Galactose-6-phosphate isomerase LacA subunit 0.42 0.54 1.10
SA2288 gtaB UTP-glucose-1-phosphate uridyltransferase 0.63 0.69 0.53
Continued on following page
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TABLE 3—Continued
ORF ID Gene Products
Ratio of signal intensitya
N315IP-
rpoB621E/
N315IP
10*3d1-SA182614A-
rpoB621E/10*3d1-
SA182614A-rpoB621A
10*3d1/
N315IP
Nitrogen metabolism
SA0008 hutH Histidine ammonia-lyase 1.27 1.50 1.25
SA0171 fdh NAD-dependent formate dehydrogenase 0.81 0.78 1.18
SA0774 ABC transporter ATP-binding protein homolog 2.85 2.95 3.28
SA0775 FeS assembly protein SufD 2.84 3.05 3.71
SA0776 Aminotransferase NifS homolog 2.76 3.12 3.41
SA0777 Similar to nitrogen fixation protein NifU 2.58 3.15 3.44
SA0778 sufB FeS assembly protein SufB 2.27 2.91 3.23
SA0779 Hypothetical protein 1.91 2.11 2.30
SA0819 gudB NAD-specific glutamate dehydrogenase 1.78 2.14 1.75
SA1241 Similar to nitric-oxide reductase 2.37 1.42 2.29
SA1310 ansA Probable L-asparaginase 1.31 1.36 1.18
dlt operon
SA0792 Hypothetical protein 1.56 2.12 0.98
SA0793 dltA D-alanine-D-alanyl carrier protein ligase 1.61 2.27 0.88
SA0794 dltB DltB membrane protein 1.60 2.54 0.81
SA0795 dltC D-alanyl carrier protein 1.55 2.60 0.83
SA0796 dltD Poly(glycerophosphate chain) D-alanine transfer protein 1.44 2.52 0.84
sigB operon
SA1869 sigB Sigma factor B 2.96 2.05 1.19
SA1870 rsbW Anti-sigmaB factor 3.15 1.90 1.14
SA1871 rsbV Anti-sigmaB factor antagonist 2.64 1.74 1.22
SA1872 rsbU SigmaB regulation protein RsbU 2.08 1.62 1.22
Riboflavin (vitamin B2)
metabolism
SA1586 ribH 6,7-Dimethyl-8-ribityllumazine synthase 1.75 1.88 2.03
SA1588 ribB Riboflavin synthase alpha chain 1.92 1.94 2.20
SA1589 ribD Riboflavin-specific deaminase 2.03 2.04 2.08
SA1587 ribA Riboflavin biosynthesis protein 2.18 1.99 2.16
Phylloquinone (vitamin K1)
and menaquinone
(vitamin K2)
metabolism
SA0898 menB Naphthoate synthase 1.08 1.30 1.33
SA1303 gerCB Menaquinone biosynthesis methyltransferase 1.14 1.00 1.16
SA0895 Similar to menaquinone-specific isochorismate synthase 1.79 1.44 2.66
SA1616 Hypothetical protein 1.85 2.12 2.37
SA0897 Similar to prolyl aminopeptidase (EC 3.4.11.5) 1.91 1.74 1.91
SA0896 menD Menaquinone biosynthesis protein 1.93 1.65 2.33
SA1615 menE O-succinylbenzoic acid-coenzyme A (CoA) ligase 2.12 1.76 2.18
SA1614 menC O-succinylbenzoic acid (OSB) synthetase 2.14 1.65 1.78
Citrate cycle (TCA cycle)
SA0944 phdB Pyruvate dehydrogenase E1 component beta subunit 1.25 0.97 0.90
SA0945 pdhC Dihydrolipoamide S-acetyltransferase component of pyruvate
dehydrogenase complex E2
1.28 1.02 0.97
SA0946 pdhD Dihydrolipoamide dehydrogenase component of pyruvate
dehydrogenase E3
0.90 1.04 1.11
SA0994 sdhC Succinate dehydrogenase cytochrome b-558 1.72 1.13 1.50
SA0995 sdhA Succinate dehydrogenase flavoprotein subunit 1.65 1.31 1.50
SA0996 sdhB Succinate dehydrogenase iron-sulfur protein subunit 1.05 1.58 1.88
SA1088 sucC Succinyl-CoA synthetase (beta subunit) 1.46 1.54 1.59
SA1089 sucD succinyl-CoA synthetase (alpha subunit) 1.11 1.52 1.62
SA1131 Similar to 2-oxoacid ferredoxin oxidoreductase, alpha subunit 1.49 1.25 1.77
SA1132 Similar to 2-oxoacid ferredoxin oxidoreductase, beta subunit 1.39 1.37 1.74
SA1184 citB Aconitate hydratase 1.07 1.11 1.59
SA1244 odhB Dihydrolipoamide succinyltransferase 1.66 1.74 1.44
SA1245 odhA 2-Oxoglutarate dehydrogenase E1 1.36 1.45 1.24
SA1349 Dihydrolipoamide dehydrogenase 1.54 0.93 1.16
SA1517 citC Isocitrate dehyrogenase 1.17 1.27 2.02
SA1518 citZ Citrate synthase II 1.03 1.18 2.11
SA1609 pckA Phosphoenolpyruvate carboxykinase (ATP) 1.27 0.82 1.10
Cell envelope and cellular
processes
SA0111 sirA Lipoprotein 2.32 2.19 0.65
SA0126 Similar to capsular polysaccharide synthesis protein 14H 0.30 0.44 0.44
SA0127 Similar to capsular polysaccharide synthesis protein 14H 0.36 0.48 0.43
Continued on following page
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MICs for them were 2, 0.5, and 2, and 2, 0.5, and 2 mg/liter,
respectively (14, 17). All the vancomycin-susceptible strains
used in this experiment were susceptible to daptomycin, while
the vancomycin-resistant strains were also resistant to dapto-
mycin (17). Figure 6 shows the summary of decreased negative
charge calculations of drug-resistant strains against their drug-
susceptible isogenic control strains. Zeta potential values for
control strain N315IP, Mu50-P35, and MI-P84 were 28 
1.4,30 1.6, and35 1.5 mV, respectively. We calculated
the ratio (percentage) of negative charge decrement in resis-
tant strains to their respective daptomycin- and vancomycin-
susceptible counterparts. It was noted that all the daptomycin-
and vancomycin-resistant strains had a decreased negative
charge compared to that of their susceptible controls (P 
0.01), and there was a positive correlation between the reduc-
tion of negative charge and the reduced susceptibility to dap-
tomycin and vancomycin (Fig. 6). The results indicated that the
decreased negative surface charge might contribute to the dap-
tomycin and vancomycin resistance in 10*3d1 as well as in
clinical VISA strains Mu50 and MI.
Rifampin resistance associated with rpoB point mutations is
a well-recognized phenomenon in S. aureus (2, 39, 50). The
TABLE 3—Continued
ORF ID Gene Products
Ratio of signal intensitya
N315IP-
rpoB621E/
N315IP
10*3d1-SA182614A-
rpoB621E/10*3d1-
SA182614A-rpoB621A
10*3d1/
N315IP
SA0265 lytM Peptidoglycan hydrolase 2.15 2.06 1.72
SA0295 Similar to outer membrane protein precursor 3.29 3.73 1.03
SA0423 sle1 Hypothetical protein, similar to autolysin (N-acetylmuramoyl-
L-alanine amidase)
2.76 2.75 2.89
SA0457 gcaD UDP-N-acetylglucosamine pyrophosphorylase 2.00 1.59 1.25
SA0523 Similar to poly(glycerol-phosphate) alpha-glucosyltransferase
(teichoic acid biosynthesis)
3.25 4.10 1.72
SA0620 stcA Secretory antigen SsaA homolog 1.81 3.16 3.05
SA0905 atl Autolysin (N-acetylmuramyl-L-alanine amidase and endo--
N-acetylglucosaminidase)
3.28 1.89 1.88
SA1023 ftsL Cell division protein 0.49 0.45 0.70
SA1026 murD UDP-N-acetylmuramoylalanine-D-glutamate ligase 2.16 1.37 1.29
SA1027 div1b Cell division protein, FtsQ homolog 2.28 1.32 1.19
SA1212 opp-2D Oligopeptide transport ATPase 1.90 2.31 2.01
SA1267 ebhA Similar to streptococcal adhesin Emb 0.30 0.12 0.64
SA1898 Similar to SceD precursor (lytic transglycosylase) 2.35 2.24 4.50
SA2097 ssaA homolog Similar to secretory antigen precursor SsaA 8.16 8.04 6.00
SA2356 isaA Immunodominant antigen A 0.38 0.60 1.22
SA2442 Preprotein translocase secA homolog 2.57 1.88 1.23
SA2446 Similar to preprotein translocase secY 2.01 2.08 2.10
SA2455 Capsular polysaccharide biosynthesis, capC 0.37 0.41 0.44
SA2456 Capsular polysaccharide biosynthesis, capB 0.38 0.38 0.40
SA2457 Capsular polysaccharide biosynthesis, capA 0.40 0.36 0.41
Other functions
SA0128 sodM Superoxide dismutase 1.51 2.04 2.12
SA0222 coa Staphylocoagulase precursor 0.46 0.64 0.14
SA0309 geh Glycerol ester hydrolase; lipase 2.29 2.03 0.83
SA0519 sdrC Ser-Asp rich fibrinogen-binding 3.35 3.04 1.15
SA0520 sdrD Ser-Asp rich fibrinogen-binding 6.25 9.58 0.58
SA0521 sdrE pfam04650, YSIRK-type signal peptide 3.21 3.30 0.52
SA0641 mgrA Transcriptional regulator, MarR family 1.81 4.00 1.74
SA0723 clpP ATP-dependent Clp protease proteolytic subunit homolog 0.46 0.71 1.00
SA0743 graB Similar to staphylocoagulase precursor 0.23 0.22 0.31
SA0746 Staphylococcal nuclease 2.35 4.54 0.74
SA1145 Hfq, an abundant, ubiquitous RNA-binding protein 0.30 0.41 0.70
SA1396 bex GTP-binding protein Era homolog 2.02 1.39 1.48
SA1452 csbD SigmaB-controlled gene product 3.04 1.82 1.60
SA1549 Similar to serine proteinase Do, heat shock protein HtrA 0.48 0.65 0.56
SA1559 Similar to smooth muscle caldesmon 2.79 1.44 0.93
SA1577 sasC Hypothetical protein, similar to FmtB protein 0.41 0.38 0.83
SA1617 Similar to latent nuclear antigen 4.69 3.16 1.90
SA1709 Similar to ferritin 1.53 2.24 2.84
SA1941 dps General stress protein 20U 1.76 3.99 4.28
SA1964 fmtB FmtB protein 0.30 0.25 0.47
SA1984 asp23 Alkaline shock protein 23, ASP23 3.26 2.00 1.25
SA2284 Similar to accumulation-associated protein 0.05 0.45 0.02
SA2285 Similar to accumulation-associated protein AAP 0.05 0.50 0.02
SA2286 sarT Helix-turn-helix multiple antibiotic resistance protein 0.45 1.03 0.36
SA2287 sarU Helix-turn-helix multiple antibiotic resistance protein 0.07 0.92 0.08
SA2290 fnbB Fibronectin-binding protein homolog 5.69 2.93 1.67
SA2423 clfB Clumping factor B 4.07 3.79 1.08
SA2430 aur Zinc metalloproteinase aureolysin 6.02 7.32 1.90
SA2431 isaB Immunodominant antigen B 2.28 4.16 1.07
a Signal intensity ratios of strains with RpoB621E versus those with RpoB621A.
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mutations are clustered predominantly in a conserved region
of RpoB, designated rifampin resistance-determining region
(RRDR), which spans amino acid residues 	463 to 550. Mu-
tations in the region result in a lessening of the hydrophobic
interaction between RpoB and rifampin and a decrease in
the binding of rifampin to RNA polymerase holoenzyme
(40). The rpoB mutation identified in 10*3d1 is located
outside the RRDR, and this coincides with the observation
that the rpoB(A621E) mutation does not affect rifampin
susceptibility of the strain (Table 2). However, the effect of
this mutation on RNA polymerase activity and the detailed
mechanism causing heteroresistance to both daptomycin
and vancomycin remains to be elucidated.
rpoB mutations are also found in clinical VISA strain Mu50
(38) and JH9 (37). Our finding of the contribution of an rpoB
mutation to daptomycin and vancomycin dual resistance in this
study indicates that the rpoB mutations also contribute to the
VISA phenotype of clinical MRSA strains.
Microarray transcriptional analysis. In our previous at-
tempt to understand the global regulatory mechanism for the
expression of daptomycin resistance in 10*3d1, we performed
microarray analysis on 10*3d1 and its parent strain N315IP.
The results, including raw signal data, were disclosed at the
CIBEX site (http://cibex.nig.ac.jp/index.jsp) under the CIBEX
accession number CBX67. By comparing the transcriptional
profiles of 10*3d1and N315IP, we identified dozens of spe-
cifically up- and downregulated genes in 10*3d1, including
those involved in cell wall and cell membrane metabolism (6).
However, since 10*3d1 had 5 single point mutations in 4 dis-
tinct genes compared to N315IP (Table 1) and all of these
mutations might have some influence on the transcriptional
profiles of 10*3d1, the alterations of transcriptional profiles of
10*3d1 might not have directly reflected the effect of the
rpoB(A621E) mutation. To better delineate the effect of the
rpoB(A621E) mutation causing dual resistance to daptomycin
and vancomycin, we performed microarray analysis of three
combinations of strains: N315IP-rpoB621E versus N315IP,
10*3d1-SA182614A-rpoB621E versus 10*3d1-SA182614A-
rpoB621A, and 10*3d1 versus N315IP (Table 2). There is only
one mutation difference [rpoB(A621E)] within each of the first
two pairs. The last pair represents the cumulative effects of the
five mutations (6).
All transcriptional profiles and comparison data are avail-
able on the CIBEX site under the accession number CBX135,
and Table 3 shows the extracted representative data. The most
significant alterations apparently caused by the rpoB(A621E)
mutation were (i) repression of the genes in the purine and
pyrimidine metabolic pathways; (ii) repression of urease genes;
(iii) enhancement of the biosynthetic pathway genes for ribo-
flavin (vitamin B2), phylloquinone (vitamin K1), and menaqui-
none (vitamin K2); and (iv) enhancement of several genes
involved in the cell envelope metabolism and structure (Table
3). It is not clear yet how the rpoB(A621E)-mediated altered
gene transcription profile mentioned above is correlated with
the phenotypic changes such as cell wall thickening, decreased
cell surface negative charge, and reduced susceptibility to van-
comycin and daptomycin. The products of the dlt operon genes
are reported to have a function of attaching positively charged
D-alanine residues onto the negatively charged phosphate
groups in the backbone of teichoic acids in S. aureus (9, 30, 41).
An enhanced expression of the dlt operon associated with an
increased cell surface positive charge was observed in dapto-
mycin-resistant MRSA (34). The singly introduced rpoB
(A621E) mutation in N315IP did enhance the expression of
dlt genes. However, curiously, the enhancement was not ap-
parent in 10*3d1 (Table 3). The same was true with the sigB
gene, whose overexpression is reported to thicken the cell wall
(35). sigB was upregulated by the rpoB(A621E) mutation in
N315IP, but the effect was not apparent in the parent strain
10*3d1 (Table 3). Besides these genes, however, there were
quite a number of genes involved in cell envelope metabo-
lism enlisted as the genes up- or downregulated by the
rpoB(A621E) mutation (Table 3). The altered expression of
such genes as sle1, atl, stcA, SA1898 (sceD homolog), SA2097
(ssaA homolog), capABC, SA0126, SA0127, SA2284, SA2285,
mgrA, fmtB, and sarUT may modify the cell envelope physiol-
ogy and structure in a way that evades the attack of vancomycin
and daptomycin.
In conclusion, although detailed studies are needed to clarify
the role of rpoB with an A621E mutation, the data presented
in this study clearly show that the rpoB mutation does confer S.
aureus cells heteroresistant to both vancomycin and daptomy-
cin. Besides the rifampin resistance phenotype, rpoB mutation
may have an important role in the multidrug-resistance phe-
notype of MRSA.
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